8-K: Apellis Pharmaceuticals Reports Strong 2023 Revenue Growth Driven by SYFOVRE Launch

Apellis Pharmaceuticals announced its fourth quarter and full year 2023 financial results, highlighting significant revenue growth driven by the successful launch of SYFOVRE and continued sales of EMPAVELI.

Summary

• Apellis Pharmaceuticals reported total revenue of $396.6 million for 2023, a significant increase from $75.4 million in 2022.
• SYFOVRE, a treatment for geographic atrophy, generated $275.2 million in U.S. net product revenue for the full year 2023, with over 160,000 doses distributed since its launch in March.
• EMPAVELI, used for treating paroxysmal nocturnal hemoglobinuria (PNH), contributed $91.0 million in U.S. net product revenue for the full year 2023.
• The company's cash and cash equivalents stood at $351.2 million as of December 31, 2023, down from $551.8 million at the end of 2022.
• Apellis expects to receive approximately $100 million from unwinding a portion of its capped call transactions related to its convertible notes.
• The company reported a net loss of $528.6 million for the full year 2023, compared to a net loss of $652.2 million in 2022.
• R&D expenses decreased to $354.4 million in 2023 from $387.2 million in 2022, while G&A expenses increased to $500.8 million from $277.2 million.

Sentiment

Score: 7

Explanation: The document presents a generally positive outlook with strong revenue growth and successful product launches, but the significant net loss and increased expenses temper the overall sentiment. The company's future prospects are promising, but there are risks and challenges to navigate.

Positives

• The launch of SYFOVRE has been very successful, exceeding expectations with strong demand and over 160,000 doses distributed.
• EMPAVELI continues to demonstrate high patient compliance rates of 97%, indicating strong patient adherence to the treatment.
• The company expects to receive approximately $100 million from unwinding a portion of its capped call transactions, strengthening its cash position.
• The company's net loss decreased from $652.2 million in 2022 to $528.6 million in 2023, showing progress in financial performance.
• The permanent J-code for SYFOVRE simplifies billing and reimbursement, which should improve access for patients.
• Data from the GALE extension study showed continued increasing treatment effects and consistent safety data for SYFOVRE over three years.
• The EMPAVELI Injector is now used by approximately 60% of existing EMPAVELI patients and greater than 90% of new EMPAVELI patients, improving ease of use.

Negatives

• The company experienced a significant net loss of $528.6 million for the full year 2023.
• Cash and cash equivalents decreased from $551.8 million at the end of 2022 to $351.2 million at the end of 2023.
• General and administrative expenses increased significantly to $500.8 million in 2023, up from $277.2 million in 2022.
• The company received a negative opinion from the CHMP regarding the marketing authorization application for SYFOVRE in Europe, requiring a re-examination.
• The Phase 3 CASCADE study of systemic pegcetacoplan for CAD was discontinued due to a realignment of development activities.
• Cost of sales increased significantly to $58.5 million in 2023 from $5.6 million in 2022.

Risks

• The company faces risks related to market conditions and the completion of the capped call unwind transactions.
• There are uncertainties regarding the re-examination of the SYFOVRE marketing authorization application with the EMA.
• The company's future performance is dependent on the continued commercial success of SYFOVRE and EMPAVELI.
• The company is subject to risks related to clinical trial outcomes and regulatory approvals for its pipeline products.
• The company's cash resources may not be sufficient to fund its operations if sales do not meet expectations or if expenses increase unexpectedly.
• The company faces risks related to serious infections caused by encapsulated bacteria with the use of EMPAVELI.

Future Outlook

Apellis anticipates its cash balance, combined with proceeds from the capped call unwind and product sales, will be sufficient to fund its operations for the foreseeable future. The company plans to continue its strong execution in 2024, focusing on expanding SYFOVRE's reach, maximizing EMPAVELI's potential, and advancing its pipeline.

Management Comments

• Cedric Francois, M.D., Ph.D., co-founder and chief executive officer of Apellis, stated that he is extremely proud of the team's accomplishments and resilience in a year faced with many highs and some unexpected challenges.
• Cedric Francois also noted that the SYFOVRE launch exceeded even their own expectations, with demand growth continuing into the first quarter of 2024.
• Management is encouraged by the uptake and high compliance rates for EMPAVELI in PNH.

Industry Context

The announcement reflects the growing market for treatments targeting complement-mediated diseases, with Apellis positioning itself as a key player in this space. The successful launch of SYFOVRE highlights the unmet need for effective treatments for geographic atrophy, while the continued growth of EMPAVELI underscores the demand for therapies in PNH. The company's focus on expanding its pipeline and global reach aligns with broader industry trends in biopharmaceuticals.

Comparison to Industry Standards

• The $275.2 million in SYFOVRE revenue in its first year of launch is a strong performance compared to other recent rare disease drug launches, such as BioMarin's Voxzogo which generated $178.4 million in its first full year.
• The 97% compliance rate for EMPAVELI is very high compared to industry averages for self-administered injectable therapies, which often see compliance rates between 50-80%.
• The increase in G&A expenses to $500.8 million is significant and may be higher than some comparable companies at a similar stage of commercialization, such as Alnylam Pharmaceuticals which reported $390 million in G&A expenses in 2023.
• The net loss of $528.6 million is substantial, but not uncommon for a biotech company investing heavily in R&D and commercialization, similar to companies like Sarepta Therapeutics which reported a net loss of $770 million in 2023.
• The cash balance of $351.2 million is adequate for the near term, but the company will likely need to raise additional capital in the future to support its pipeline and commercial expansion, similar to other biotech companies in the growth phase.

Stakeholder Impact

• Shareholders will be impacted by the financial results, including the revenue growth and net loss.
• Employees may be affected by the company's growth and expansion plans.
• Patients will benefit from the continued availability and expansion of SYFOVRE and EMPAVELI.
• Suppliers and creditors will be impacted by the company's financial performance and cash flow.

Next Steps

• The company will continue to focus on bringing SYFOVRE to more patients in the U.S. and globally.
• Apellis will work to maximize EMPAVELI in PNH and C3G/IC-MPGN.
• The company will advance its earlier-stage pipeline.
• Apellis will continue to work on the re-examination of the marketing authorization application of SYFOVRE with the EMA.
• The company will await topline data from the Phase 3 VALIANT study in mid-2024.
• The company will continue to enroll patients in the Phase 2 study evaluating systemic pegcetacoplan in patients with HSCT-TMA.
• The company will continue the Phase 1 dose escalation study of APL-3007 with topline data expected in 2024.

Key Dates

Keywords

SYFOVRE, EMPAVELI, pegcetacoplan, geographic atrophy, paroxysmal nocturnal hemoglobinuria, revenue, financial results, capped call, clinical trials, biopharmaceutical